OSE Immunotherapeutics Announces Procedures for Virtual Combined General Meeting - Seite 2

• Appointment of scrutineers

In accordance with Decree No. 2020-418, the Company’s Board of Directors has decided to appoint the following shareholders as scrutineers:

- Mrs. Maryvonne Hiance, shareholder and Vice-Chairman of the Board of Directors;

- Mr. Alexis Peyroles, shareholder and CEO of the Company.

The General Meeting will be chaired by Mrs. Dominique Costantini, Chairwoman of the Board of Directors.

The Bureau thus constituted will be responsible for ensuring the proper performance of the General Meeting. It will be accompanied by CIC Market Solutions (middle office service of the issuer) which will collect and count the votes of shareholders in registered form or having voted by proxy.

• Reminder of voting procedures

To be taken into account, the duly completed and signed forms must be received no later than the second day preceding the date of the Meeting, i.e. no later than June 22, 2021.

For registered shareholders: they must return the voting form which will be sent to them with the convening notice either by post to CIC Market Solutions (Service Assemblées - 6 Avenue de Provence - 75452 Paris Cedex 09 - France), or by email to the address: [e-mail].

For bearer shareholders: they can request this voting form from the bank or financial intermediary that manages their securities, from the date of notice of meeting. Once completed and signed, the form will be returned by the shareholder along with a certificate of participation either by post to CIC Market Solutions (Service Assemblées, 6 Avenue de Provence - 75452 Paris Cedex 09) or by email to the address: [e-mail].

Shareholders are invited to regularly consult the section dedicated to the General Meeting on the Company's website:

https://ose-immuno.com/en/general-shareholders-meetings/

where they will find preparatory documents, including the voting form.

ABOUT OSE Immunotherapeutics
OSE Immunotherapeutics is an integrated biotechnology company focused on developing and partnering therapies to control the immune system for immuno-oncology and autoimmune diseases. The company’s immunology research and development platform is focused on three areas: T-cell-based vaccination, Immuno-Oncology (focus on myeloid targets), Auto-immunity & Inflammation. Its balanced first-in-class clinical and preclinical portfolio has a diversified risk profile: